Evidence map›Paper›PMID 39271965›Full record

ArticleOncogene2024

Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesis.

Clarissa N Pacyna, Madhanagopal Anandapadamanaban, Kevin W Loudon, Iain M Hay, Olga Perisic, Ruoyan Li, Matthew Byrne, Laura Allen, Kirsty Roberts, Yvette Hooks and 8 more

Abstract readCase Reports
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Making PI3K superfamily enzymes run faster.Advances in biological regulation · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Clarissa N Pacyna *Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.ORCID 0000-0002-4404-8183
Madhanagopal Anandapadamanaban *MRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
Kevin W LoudonCambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, CB2 0QQ, UK.
Iain M HayMRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
Olga PerisicMRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
Ruoyan LiDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-5337-9729
Matthew ByrneWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Laura AllenWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Kirsty RobertsWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Yvette HooksWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Anne Y WarrenCambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, CB2 0QQ, UK.ORCID 0000-0002-1170-7867
Grant D StewartCambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, CB2 0QQ, UK.ORCID 0000-0003-3188-9140
Menna R ClatworthyWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Sarah A TeichmannWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Sam BehjatiWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.ORCID 0000-0002-6600-7665
Peter J CampbellWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.ORCID 0000-0002-3921-0510
Roger L WilliamsMRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK. rlw@mrc-lmb.cam.ac.uk.ORCID 0000-0001-7754-4207
Thomas J MitchellWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK. tjm61@medschl.cam.ac.uk.ORCID 0000-0003-0761-9503

Funding

Cancer Research UK (CRUK) DRCPGM\100014European Molecular Biology Organization (EMBO) EMBO ALTF 603-2019Medical Research Council MC_PC_17230Wellcome TrustWellcome Trust 206194Wellcome Trust (Wellcome) 223135/Z/21/Z
6 · The paper itself

Abstract

Embryogenesis is a vulnerable time. Mutations in developmental cells can result in the wide dissemination of cells predisposed to disease within mature organs. We characterised the evolutionary history of four synchronous renal tumours from a 14-year-old girl using whole genome sequencing alongside single cell and bulk transcriptomic sequencing. Phylogenetic reconstruction timed the origin of all tumours to a multipotent embryonic cell committed to the right kidney, around 4 weeks post-conception. Biochemical and structural analysis of their shared MTOR mutation, absent from normal tissues, demonstrates enhanced protein flexibility, enabling a FAT domain hinge to dramatically increase activity of mTORC1 and mTORC2. Developmental mutations, not usually detected in traditional genetic screening, have vital clinical importance in guiding prognosis, targeted treatment, and family screening decisions for paediatric tumours.

Indexed as

Kidney NeoplasmsMutationTOR Serine-Threonine KinasesAdultEmbryonic DevelopmentFemaleHumansMechanistic Target of Rapamycin Complex 1Middle AgedPhylogenyYoung AdultMechanistic Target of Rapamycin Complex 1MTOR protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID39271965
PMCPMC11518995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.